title: A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
abstract: We have previously demonstrated that vaccination with a subunit dengue vaccine containing a consensus envelope domain III with aluminum phosphate elicits neutralizing antibodies against all four serotypes of dengue virus in mice. In this study, we evaluated the immunogenicity of the subunit dengue vaccine in non-human primates. After vaccination, monkeys that received the subunit vaccine with aluminum phosphate developed a significantly strong and long-lasting antibody response. A specific T cell response with cytokine production was also induced, and this correlated with the antibody response. Additionally, neutralizing antibodies against serotype 2 were detected in two of three monkeys. The increase in serotype-2-specific antibody titers and avidity observed in these two monkeys suggested that a serotype-2-biased antibody response occurs. These data provide evidence that a protective neutralizing antibody response was successfully elicited in non-human primates by the dengue subunit vaccine with aluminum phosphate adjuvant.
authors: National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli, Taiwan.
authors: Hsin-Wei
authors: HW
authors: Chen
authors: Shih-Jen
authors: SJ
authors: Liu
authors: Yi-Shiuan
authors: YS
authors: Li
authors: Hsueh-Hung
authors: HH
authors: Liu
authors: Jy-Ping
authors: JP
authors: Tsai
authors: Chen-Yi
authors: CY
authors: Chiang
authors: Mei-Yu
authors: MY
authors: Chen
authors: Chyi-Sing
authors: CS
authors: Hwang
authors: Chin-Cheng
authors: CC
authors: Huang
authors: Hui-Mei
authors: HM
authors: Hu
authors: Han-Hsuan
authors: HH
authors: Chung
authors: Sze-Hsien
authors: SH
authors: Wu
authors: Pele
authors: P
authors: Chong
authors: Chih-Hsiang
authors: CH
authors: Leng
authors: Chien-Hsiung
authors: CH
authors: Pan
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D017607:Aluminum Compounds / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D000915:Antibody Affinity; D016207:Cytokines / Q000378:metabolism; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D003716:Dengue Virus / Q000235:genetics / Q000276:immunology*; D000882:Haplorhini; D010710:Phosphates / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D016207:Cytokines; D053059:Dengue Vaccines; C051821:E-glycoprotein, Dengue virus type 2; D010710:Phosphates; D022223:Vaccines, Subunit; D014759:Viral Envelope Proteins; C012714:aluminum phosphate